Answers are grounded in this paper and cite their sources.
Preclinical investigation demonstrates tumor-specific cell surface expression of CLDN18.2 across human epithelial cancers, highlighting its viability as an antibody drug target.
Its highly restricted expression pattern in normal tissues, its frequent ectopic activation in a diversity of human cancers, and the ability to specifically target this molecule at the cell surface of tumor cells qualify CLDN18.2 as a novel, highly attractive pan-cancer target for the antibody therapy of epithelial tumors.
No takes yet. Share an insight, caveat, or question.
Şahin et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: